<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Ther</journal-id><journal-id journal-id-type="iso-abbrev">Adv Ther</journal-id><journal-title-group><journal-title>Advances in Therapy</journal-title></journal-title-group><issn pub-type="ppub">0741-238X</issn><issn pub-type="epub">1865-8652</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26100349</article-id><article-id pub-id-type="pmc">4487350</article-id><article-id pub-id-type="publisher-id">216</article-id><article-id pub-id-type="doi">10.1007/s12325-015-0216-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD<sup>&#x000ae;</sup></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Vogelmeier</surname><given-names>Claus F.</given-names></name><address><email>claus.vogelmeier@med.uni-marburg.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Asijee</surname><given-names>Guus M.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kupas</surname><given-names>Katrin</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Beeh</surname><given-names>Kai M.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Department of Internal Medicine, Division for Pulmonary Diseases, Hospital of the University of Giessen and Marburg, Marburg, Germany </aff><aff id="Aff2"><label/>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG, Ingelheim am Rhein, Germany </aff><aff id="Aff3"><label/>Independent Statistical Consultant, Frankfurt, Germany </aff><aff id="Aff4"><label/>insaf Respiratory Research Institute, Wiesbaden, Germany </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>32</volume><issue>6</issue><fpage>537</fpage><lpage>547</lpage><history><date date-type="received"><day>18</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Among patients with chronic obstructive pulmonary disease (COPD), the frequency and severity of past exacerbations potentiates future events. The impact of current therapies on exacerbation frequency and severity in patients with different exacerbation risks is not well known.</p></sec><sec><title>Methods</title><p>A post hoc analysis of patients at low (&#x02264;1 exacerbation [oral steroids/antibiotics requirement] and no COPD-related hospitalization in the year preceding trial entry) or high (&#x02265;2 exacerbations [oral steroids/antibiotics requirement] or &#x02265;1 COPD-related hospitalization[s] in the year preceding trial entry) exacerbation risk, from the Prevention of Exacerbations with Tiotropium in Chronic Obstructive Pulmonary Disease (POET-COPD<sup>&#x000ae;</sup>) database.</p></sec><sec><title>Results</title><p>Compared with salmeterol, tiotropium significantly increased time to first COPD exacerbation (hazard ratio 0.84; 95% confidence interval [CI] 0.76&#x02013;0.92; <italic>p</italic>&#x000a0;=&#x000a0;0.0002) and reduced the number of COPD exacerbations (rate ratio 0.90; 95% CI 0.81&#x02013;0.99; <italic>p</italic>&#x000a0;=&#x000a0;0.0383) in patients at high exacerbation risk. With treatment, the risk of remaining in the high-risk exacerbator subgroup was statistically lower with tiotropium versus salmeterol (risk ratio [RR] 0.89; 95% CI 0.80&#x02013;1.00; <italic>p</italic>&#x000a0;=&#x000a0;0.0478). For low-risk patients, time to first COPD exacerbation and number of COPD exacerbations were numerically lower with tiotropium versus salmeterol. With treatment, the risk of transitioning from a low to a high exacerbation risk was lower with tiotropium versus salmeterol (RR 0.87; 95% CI 0.71&#x02013;1.07; <italic>p</italic>&#x000a0;=&#x000a0;0.1968).</p></sec><sec><title>Discussion</title><p>This analysis confirms the higher efficacy of tiotropium versus salmeterol in prolonging time to first COPD exacerbation and reducing number of exacerbations in patients both at low and high exacerbation risk.</p></sec><sec><title>Funding</title><p>Boehringer Ingelheim and Pfizer.</p><p>Clinical trial registration number: ClinicalTrials.gov NCT00563381.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s12325-015-0216-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COPD</kwd><kwd>Exacerbations</kwd><kwd>POET-COPD<sup>&#x000ae;</sup></kwd><kwd>Tiotropium</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Exacerbations have a deleterious effect on the morbidity and mortality of patients with chronic obstructive pulmonary disease (COPD) [<xref ref-type="bibr" rid="CR1">1</xref>] by increasing hospitalization [<xref ref-type="bibr" rid="CR2">2</xref>], worsening lung function [<xref ref-type="bibr" rid="CR3">3</xref>] and health-related quality of life, and decreasing survival [<xref ref-type="bibr" rid="CR4">4</xref>]. As such, the prevention of exacerbations is an important goal of COPD therapy [<xref ref-type="bibr" rid="CR5">5</xref>], the importance of which is reflected in the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) document on the management of COPD [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The frequency of exacerbations increases in parallel with the severity of COPD [<xref ref-type="bibr" rid="CR7">7</xref>]. In the Evaluation of&#x000a0;COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE<sup>&#x000ae;</sup>) (ClinicalTrials.gov #NCT00292552) observational study of patients with COPD, exacerbation rate was shown to increase with GOLD staging, such that 22% of patients with GOLD Stage II disease had two or more exacerbations during 1&#x000a0;year of follow-up, whereas 47% of patients with GOLD Stage IV disease had frequent exacerbations over the same period. Across all GOLD stages, the single best predictor of future episodes was prior exacerbations [<xref ref-type="bibr" rid="CR8">8</xref>]. Additionally, the results from the ECLIPSE study suggested that patients with COPD could be phenotyped according to their exacerbation risk. Those patients who experienced fewer than two exacerbations per year were classified as &#x0201c;infrequent exacerbators&#x0201d;; those experiencing two or more per year were classified as &#x0201c;frequent exacerbators&#x0201d; and considered to be different phenotypes [<xref ref-type="bibr" rid="CR8">8</xref>]. More recently, the GOLD 2013 guidelines revisited this classification of patients at risk for exacerbations and divided patients into low (&#x02264;1 exacerbations; no severe exacerbations) and high (&#x02265;2 or &#x02265;1 severe exacerbation) risk categories [<xref ref-type="bibr" rid="CR6">6</xref>]. The critical difference between these classification systems is that, according to the ECLIPSE classification, one hospitalization (severe exacerbation) would suggest an infrequent exacerbator, whereas it would suggest a high-risk exacerbator according to the new GOLD classification [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Few studies have investigated the effect of pharmacotherapy on COPD exacerbations in different subsets of exacerbator phenotype patients. The Prevention of Exacerbations with Tiotropium in Chronic Obstructive Pulmonary Disease (POET-COPD<sup>&#x000ae;</sup>) (ClinicalTrials.gov NCT00563381) study was a 1-year, randomized, double-blind, double-dummy, parallel-group trial that compared the effect of treatment with the long-acting anticholinergic tiotropium (18&#x000a0;&#x003bc;g via the HandiHaler<sup>&#x000ae;</sup> device once daily) (SPIRIVA<sup>&#x000ae;</sup>, Boehringer Ingelheim Pharma and Co. KG, Ingelheim, Germany) with that of the long-acting &#x003b2;<sub>2</sub>-agonist (LABA) salmeterol (50&#x000a0;&#x003bc;g via a hydrofluoroalkane-pressurized metered-dose inhaler twice daily) on the incidence of moderate and severe exacerbations in 7376 patients with COPD and a history of exacerbations in the preceding year [<xref ref-type="bibr" rid="CR9">9</xref>]. The POET-COPD trial showed that, among the total patient population, tiotropium as compared with salmeterol (1) increased the time to the first exacerbation, (2) significantly increased the time to the first severe exacerbation, and (3) reduced the annual number of moderate or severe exacerbations [<xref ref-type="bibr" rid="CR9">9</xref>]. However, the impact of tiotropium and salmeterol specifically on patients at low or high risk of exacerbations has not been established.</p><p>The current study therefore investigated the effect of tiotropium and salmeterol on exacerbations in patients considered to be at a low or high risk for exacerbations (GOLD guidelines 2014 classification) and frequent/infrequent exacerbators (ECLIPSE study criteria) during a 1-year treatment period in a post hoc analysis of patients in the POET-COPD trial.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study Design</title><p>POET-COPD was a 1-year, randomized, double-blind, double-dummy, parallel-group trial that analyzed the effect of tiotropium 18&#x000a0;&#x003bc;g once daily or salmeterol 50&#x000a0;&#x003bc;g twice daily on moderate to severe exacerbations in patients with COPD [<xref ref-type="bibr" rid="CR9">9</xref>]. The primary endpoint of the trial was time to first moderate or severe exacerbation. Secondary and safety endpoints included time to event, number of events, serious adverse events, and mortality. An exacerbation was defined as an increase in, or new onset of, at least two respiratory symptoms (cough, sputum, dyspnea, wheezing, chest tightness) with at least one symptom lasting for &#x02265;3&#x000a0;days and leading the patient&#x02019;s attending physician to initiate treatment with systemic corticosteroids and/or antibiotics (moderate exacerbation) or request hospitalization (severe exacerbation) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Patients receiving fixed-dose combinations of LABAs and inhaled corticosteroids (ICS) switched to ICS monotherapy (on equal ICS dose) at the start of randomized treatment. All COPD medications, except for anticholinergics or LABAs, were permitted during the double-blind treatment phase. Inclusion criteria were age &#x02265;40&#x000a0;years, smoking history &#x02265;10 pack-years, diagnosis of COPD (post-bronchodilator forced expiratory volume in 1&#x000a0;s [FEV<sub>1</sub>] &#x02264;70% predicted and FEV<sub>1</sub>/forced vital capacity &#x02264;70%), and at least one exacerbation in the previous year requiring treatment with systemic steroids and/or antibiotics and/or hospitalization.</p></sec><sec id="Sec4"><title>Statistical Analysis</title><p>The statistical tests were designed to test the hypothesis that tiotropium had a greater efficacy than salmeterol in preventing future exacerbations. Post hoc analyses were performed by the subgroups that were low/high risk at baseline and based on collected COPD characteristics, including hospitalization due to an exacerbation and medication use. A Cox proportional hazards regression model was used for time-to-exacerbation analyses. Hazard ratios (HR) and <italic>p</italic> values were based on stratified Cox regression with treatment as covariate. Poisson regression correcting for overdispersion and adjusting for treatment exposure and with terms for subgroup and treatment-by-subgroup interaction was used for number-of-event (exacerbations) analyses. The probability of a patient being considered at high risk for exacerbations during 1&#x000a0;year of treatment in the POET-COPD study was analyzed using a log-binomial model adjusting for treatment exposure and with terms for subgroup and treatment-by-subgroup interaction. A post hoc subgroup analysis was conducted to compare patients in each study group who were and were not receiving ICS at baseline. Statistical analyses were conducted using SAS<sup>&#x000ae;</sup> version 9.2, SAS Institute Inc. 2009, Cary, North Carolina, USA.</p><p>This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.</p></sec></sec><sec id="Sec5" sec-type="results"><title>Results</title><p>The baseline characteristics of patients stratified according to low/high exacerbation risk is summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Except for baseline lung function and baseline ICS use, patients in the low-risk (<italic>n</italic>&#x000a0;=&#x000a0;2610) and high-risk (<italic>n</italic>&#x000a0;=&#x000a0;4284) groups were balanced. Within the risk subgroups, there were no clinically relevant differences in the baseline characteristics of patients in the tiotropium and salmeterol groups (data not shown).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of patients in each risk group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Low risk (<italic>N</italic>&#x000a0;=&#x000a0;2610)</th><th align="left">High risk (<italic>N</italic>&#x000a0;=&#x000a0;4284)</th></tr></thead><tbody><tr><td align="left">Age, years</td><td char="(" align="char">63.4 (8.8)</td><td char="(" align="char">62.7 (9.1)</td></tr><tr><td align="left">Male, <italic>n</italic> (%)</td><td char="(" align="char">1946 (74.6)</td><td char="(" align="char">3220 (75.2)</td></tr><tr><td align="left" colspan="3">Smoking status, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Ex-smoker</td><td char="(" align="char">1331 (51.0)</td><td char="(" align="char">2279 (53.2)</td></tr><tr><td align="left">&#x000a0;Current smoker</td><td char="(" align="char">1278 (49.0)</td><td char="(" align="char">2005 (46.8)</td></tr><tr><td align="left">Time since diagnosis of COPD, years</td><td char="(" align="char">7.4 (6.5)</td><td char="(" align="char">8.3 (6.8)</td></tr><tr><td align="left" colspan="3">Spirometry</td></tr><tr><td align="left">&#x000a0;FEV<sub>1</sub>, L</td><td char="(" align="char">1.47 (0.47)</td><td char="(" align="char">1.37 (0.45)</td></tr><tr><td align="left">&#x000a0;FEV<sub>1</sub>, % predicted</td><td char="(" align="char">51.1 (13.0)</td><td char="(" align="char">48.0 (13.3)</td></tr><tr><td align="left" colspan="3">Respiratory medication taken at baseline, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Anticholinergics</td><td char="(" align="char">1391 (53)</td><td char="(" align="char">2342 (55)</td></tr><tr><td align="left">&#x000a0;ICS</td><td char="(" align="char">1308 (50)</td><td char="(" align="char">2411 (56)</td></tr><tr><td align="left">&#x000a0;Other steroids</td><td char="(" align="char">43 (1.6)</td><td char="(" align="char">125 (3)</td></tr><tr><td align="left">&#x000a0;LABA</td><td char="(" align="char">1355 (52)</td><td char="(" align="char">2239 (52)</td></tr><tr><td align="left">&#x000a0;ICS&#x000a0;+&#x000a0;LABA (free or FDC)</td><td char="(" align="char">1097 (42)</td><td char="(" align="char">1929 (45)</td></tr></tbody></table><table-wrap-foot><p>Data are mean (SD) unless otherwise specified</p><p>
<italic>COPD</italic> chronic obstructive pulmonary disease, <italic>FDC</italic> fixed-dose combination, <italic>FEV</italic>
<sub><italic>1</italic></sub> forced expiratory volume in 1&#x000a0;s, <italic>ICS</italic> inhaled corticosteroids, <italic>LABA</italic> long-acting &#x003b2;<sub>2</sub>-agonist, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p><sec id="Sec6"><title>Time to First COPD Exacerbation</title><p>Using the GOLD 2013 risk classification for exacerbations, tiotropium reduced the risk of a COPD exacerbation compared with salmeterol in patients classified as being at high risk or low risk for exacerbations (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A similar pattern was obtained when using the frequent/infrequent risk classification definition. Tiotropium also increased the time to first COPD exacerbation compared with salmeterol in patients classified as being at high risk for exacerbations (HR 0.84; 95% confidence interval [CI] 0.76&#x02013;0.92; <italic>p</italic>&#x000a0;=&#x000a0;0.0002) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In those patients classified as being at low risk for exacerbations, there was a non-significant increase in time to first COPD exacerbation for tiotropium compared with salmeterol (HR 0.89; 95% CI 0.77&#x02013;1.02; <italic>p</italic>&#x000a0;=&#x000a0;0.1046) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Cumulative risk of COPD exacerbations on treatment by patient exacerbation risk classification. <italic>COPD</italic> chronic obstructive pulmonary disease</p></caption><graphic xlink:href="12325_2015_216_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Time to first COPD exacerbation by patient exacerbation risk classification</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient classification</th><th align="left" colspan="2">Tiotropium</th><th align="left" colspan="2">Salmeterol</th><th align="left" colspan="2">Tiotropium vs. salmeterol</th></tr><tr><th align="left">
<italic>n</italic>
</th><th align="left">Number of patients with events</th><th align="left">
<italic>n</italic>
</th><th align="left">Number of patients with events</th><th align="left">HR (95% CI)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Low risk</td><td char="." align="char">1324</td><td char="." align="char">375</td><td char="." align="char">1286</td><td char="." align="char">402</td><td char="(" align="char">0.89 (0.77&#x02013;1.02)</td><td align="left">0.1046</td></tr><tr><td align="left">High risk</td><td char="." align="char">2132</td><td char="." align="char">824</td><td char="." align="char">2152</td><td char="." align="char">993</td><td char="(" align="char">0.84 (0.76&#x02013;0.92)</td><td align="left">0.0002</td></tr><tr><td align="left">Infrequent exacerbator</td><td char="." align="char">1531</td><td char="." align="char">434</td><td char="." align="char">1484</td><td char="." align="char">472</td><td char="(" align="char">0.87 (0.77&#x02013;0.99)</td><td align="left">0.0414</td></tr><tr><td align="left">Frequent exacerbator</td><td char="." align="char">1878</td><td char="." align="char">748</td><td char="." align="char">1901</td><td char="." align="char">843</td><td char="(" align="char">0.84 (0.76&#x02013;0.93)</td><td align="left">0.0005</td></tr></tbody></table><table-wrap-foot><p>
<italic>CI</italic> confidence interval, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>HR</italic> hazard ratio</p></table-wrap-foot></table-wrap></p><p>A similar pattern was obtained when using the frequent/infrequent risk classification definition. Tiotropium significantly increased the time to first COPD exacerbation compared with salmeterol in frequent exacerbators (HR 0.84; 95% CI 0.76&#x02013;0.93; <italic>p</italic>&#x000a0;=&#x000a0;0.0005) and infrequent exacerbators (HR 0.87; 95% CI 0.77&#x02013;0.99; <italic>p</italic>&#x000a0;=&#x000a0;0.0414) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Whether or not patients were on background ICS at baseline did not impact these results (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Time to first COPD exacerbation by patient exacerbation risk history classification and ICS use at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient classification</th><th align="left" colspan="2">Tiotropium</th><th align="left" colspan="2">Salmeterol</th><th align="left" colspan="2">Tiotropium vs. salmeterol</th></tr><tr><th align="left">
<italic>n</italic>
</th><th align="left">Number of patients with events</th><th align="left">
<italic>n</italic>
</th><th align="left">Number of patients with events</th><th align="left">HR (95% CI)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Low risk (&#x02212;ICS)</td><td char="." align="char">656</td><td char="." align="char">151</td><td char="." align="char">646</td><td char="." align="char">171</td><td char="(" align="char">0.85 (0.68&#x02013;1.06)</td><td char="." align="char">0.1415</td></tr><tr><td align="left">Low risk (+ICS)</td><td char="." align="char">668</td><td char="." align="char">224</td><td char="." align="char">640</td><td char="." align="char">231</td><td char="(" align="char">0.92 (0.76&#x02013;1.10)</td><td char="." align="char">0.3638</td></tr><tr><td align="left">High risk (&#x02212;ICS)</td><td char="." align="char">924</td><td char="." align="char">305</td><td char="." align="char">949</td><td char="." align="char">368</td><td char="(" align="char">0.81 (0.69&#x02013;0.94)</td><td char="." align="char">0.0054</td></tr><tr><td align="left">High risk (+ICS)</td><td char="." align="char">1208</td><td char="." align="char">519</td><td char="." align="char">1203</td><td char="." align="char">565</td><td char="(" align="char">0.85 (0.76&#x02013;0.96)</td><td char="." align="char">0.0086</td></tr></tbody></table><table-wrap-foot><p>
<italic>CI</italic> confidence interval, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>HR</italic> hazard ratio, <italic>ICS</italic> inhaled corticosteroid</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>Number of COPD Exacerbations (Adjusted Annual Rates)</title><p>Tiotropium significantly reduced the number of COPD exacerbations compared with salmeterol in patients classified as being at high risk for exacerbations (rate ratio [RR] 0.90; 95% CI 0.81&#x02013;0.99; <italic>p</italic>&#x000a0;=&#x000a0;0.0383; adjusted annual rates&#x000a0;=&#x000a0;0.76 and 0.85 for tiotropium and salmeterol, respectively) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). When using the frequent/infrequent risk classification, there was a borderline significant reduction with tiotropium in the number of COPD exacerbations compared with salmeterol in patients classified as frequent exacerbators (RR 0.90; 95% CI 0.81&#x02013;1.01; <italic>p</italic>&#x000a0;=&#x000a0;0.0668; adjusted annual rates&#x000a0;=&#x000a0;0.79 and 0.87 for tiotropium and salmeterol, respectively) and also in the number of COPD exacerbations compared with salmeterol in patients classified as infrequent exacerbators (RR 0.88; 95% CI 0.75&#x02013;1.02; <italic>p</italic>&#x000a0;=&#x000a0;0.0881; adjusted annual rates&#x000a0;=&#x000a0;0.48 and 0.55 for tiotropium and salmeterol, respectively) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In patients classified as being at low risk for exacerbations, there was a borderline significant reduction with tiotropium in the number of COPD exacerbations compared with salmeterol (RR 0.89; 95% CI 0.76&#x02013;1.05; <italic>p</italic>&#x000a0;=&#x000a0;0.1768; adjusted annual rates&#x000a0;=&#x000a0;0.48 and 0.54 for tiotropium and salmeterol, respectively) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The post hoc subgroup analysis comparing both high- and low-risk patients who were or were not receiving ICS at baseline showed similar trends towards tiotropium reducing the number of COPD exacerbations; however, in high-risk patients receiving ICS at baseline, this was a numerical difference only (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Number of COPD exacerbations after treatment by patient exacerbation risk classification. <italic>CI</italic> confidence interval, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>RR</italic> risk ratio</p></caption><graphic xlink:href="12325_2015_216_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Number of COPD exacerbations after treatment by patient exacerbation risk classification and ICS use at baseline. <italic>CI</italic> confidence interval, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>ICS</italic> inhaled corticosteroid, <italic>RR</italic> risk ratio</p></caption><graphic xlink:href="12325_2015_216_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec8"><title>Treatment-Induced Shifts in Patient Risk Classification</title><p>Comparing patients at low versus high risk for exacerbations before and after 1&#x000a0;year&#x02019;s treatment with either tiotropium or salmeterol showed that treatment resulted in a shift in the ratio (low/high exacerbation risk) from 0.62 to 4.98 and from 0.60 to 4.25 for treatment with tiotropium and salmeterol, respectively (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). When using the infrequent versus frequent for exacerbations definition, shifts in the ratio (infrequent/frequent exacerbations) were larger (from 0.82 to 6.44 and from 0.78 to 5.80 for treatment with tiotropium and salmeterol, respectively) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The risk of remaining in the high-risk subgroup for exacerbations after 1&#x000a0;year of treatment was statistically lower in the tiotropium group than in the salmeterol group (RR 0.89; 95% CI 0.80&#x02013;1.00; <italic>p</italic>&#x000a0;=&#x000a0;0.0478) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). The risk of patients who were in the low-risk subgroup for exacerbations in the previous year being considered at high risk for exacerbations after 1&#x000a0;year&#x02019;s treatment was statistically lower in the tiotropium group compared with salmeterol (RR 0.87; 95% CI 0.71&#x02013;1.07; <italic>p</italic>&#x000a0;=&#x000a0;0.1968) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Comparison of patient classifications before and during treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Risk classification</th><th align="left" colspan="2">ECLIPSE<sup>&#x000ae;</sup> exacerbation frequency definition (frequent/infrequent exacerbator)<break/>
<italic>N</italic>&#x000a0;=&#x000a0;6794</th><th align="left" colspan="2">GOLD 2013/4 risk definition (high risk/low risk)<break/>
<italic>N</italic>&#x000a0;=&#x000a0;6894</th></tr><tr><th align="left">Tiotropium</th><th align="left">Salmeterol</th><th align="left">Tiotropium</th><th align="left">Salmeterol</th></tr></thead><tbody><tr><td align="left">Before 1&#x000a0;year of treatment (low/infrequent), <italic>n</italic>
<sup>a</sup> (%)</td><td align="left">1531 (22.5)</td><td align="left">1484 (21.8)</td><td align="left">1324 (19.2)</td><td align="left">1286 (18.7)</td></tr><tr><td align="left">During 1&#x000a0;year of treatment (low/infrequent), <italic>n</italic>
<sup>a</sup> (%)</td><td align="left">2951 (43.4)</td><td align="left">2887 (42.5)</td><td align="left">3087 (44.8)</td><td align="left">2970 (43.1)</td></tr><tr><td align="left">Before 1&#x000a0;year of treatment (high/frequent), <italic>n</italic>
<sup>a</sup> (%)</td><td align="left">1878 (27.6)</td><td align="left">1901 (28.0)</td><td align="left">2132 (30.9)</td><td align="left">2152 (31.2)</td></tr><tr><td align="left">During 1&#x000a0;year of treatment (high/frequent), <italic>n</italic>
<sup>a</sup> (%)</td><td align="left">458 (6.7)</td><td align="left">498 (7.3)</td><td align="left">620 (9.0)</td><td align="left">699 (10.1)</td></tr><tr><td align="left">Ratio infrequent (low risk)/frequent (high risk) during 1&#x000a0;year before study</td><td align="left">0.82</td><td align="left">0.78</td><td align="left">0.62</td><td align="left">0.60</td></tr><tr><td align="left">Ratio infrequent (low risk)/frequent (high risk) on treatment</td><td align="left">6.44</td><td align="left">5.80</td><td align="left">4.98</td><td align="left">4.25</td></tr><tr><td align="left">Ratio difference (on treatment&#x02014;before study)</td><td align="left">5.62</td><td align="left">5.02</td><td align="left">4.36</td><td align="left">3.65</td></tr></tbody></table><table-wrap-foot><p>
<italic>ECLIPSE</italic>
<sup><italic>&#x000ae;</italic></sup> Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints, <italic>GOLD</italic> Global Initiative for Chronic Obstructive Lung Disease</p><p>
<sup>a</sup>Total patient population</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Probability of shifts to high-risk/frequent exacerbator group with tiotropium and salmeterol treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Prior to treatment</th><th align="left" colspan="4">On-treatment Exacerbation frequency, <italic>n</italic> (%)</th><th align="left" colspan="2">Probability of shifting to high-risk/frequent exacerbator category (tiotropium versus salmeterol)</th></tr><tr><th align="left" colspan="2">Low risk/infrequent</th><th align="left" colspan="2">High risk/frequent</th><th align="left" rowspan="2">RR (95% CI)</th><th align="left" rowspan="2">
<italic>p</italic> value</th></tr><tr><th align="left">Tiotropium</th><th align="left">Salmeterol</th><th align="left">Tiotropium</th><th align="left">Salmeterol</th></tr></thead><tbody><tr><td align="left">Low risk</td><td char="(" align="char">1172 (88.5)</td><td char="(" align="char">1117 (86.9)</td><td char="(" align="char">152 (11.5)</td><td char="(" align="char">169 (13.1)</td><td char="(" align="char">0.87 (0.71&#x02013;1.07)</td><td char="." align="char">0.1968</td></tr><tr><td align="left">High risk</td><td char="(" align="char">1692 (79.4)</td><td char="(" align="char">1654 (76.9)</td><td char="(" align="char">440 (20.6)</td><td char="(" align="char">498 (23.1)</td><td char="(" align="char">0.89 (0.80&#x02013;1.00)</td><td char="." align="char">0.0478</td></tr><tr><td align="left">Infrequent exacerbator</td><td char="(" align="char">1382 (90.3)</td><td char="(" align="char">1326 (89.4)</td><td char="(" align="char">149 (9.7)</td><td char="(" align="char">158 (10.6)</td><td char="(" align="char">0.91 (0.74&#x02013;1.13)</td><td char="." align="char">0.4065</td></tr><tr><td align="left">Frequent exacerbator</td><td char="(" align="char">1569 (83.5)</td><td char="(" align="char">1561 (82.1)</td><td char="(" align="char">309 (16.5)</td><td char="(" align="char">340 (17.9)</td><td char="(" align="char">0.92 (0.80&#x02013;1.06)</td><td char="." align="char">0.2436</td></tr></tbody></table><table-wrap-foot><p>
<italic>CI</italic> confidence interval, <italic>RR</italic> risk ratio</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>This post hoc analysis of the POET-COPD trial, which investigated the effect of tiotropium and salmeterol on exacerbations in patients considered to be at a low or high risk for exacerbations during the 1-year treatment period, had two main findings. First, it confirmed the higher efficacy of tiotropium compared with salmeterol in prolonging the time to first COPD exacerbation and reducing the number of COPD exacerbations in patients considered to be at low risk, as well as in those considered to be at high risk, for exacerbations. Second, our results show that background ICS usage at baseline, or lack thereof, had no impact on tiotropium&#x02019;s efficacy (versus salmeterol) with regard to reducing the exacerbation frequency among patients with COPD, regardless of their risk classification. Although the original trial was not set up to test this, tiotropium, and to a lesser extent salmeterol, appears to shift patients in the high-risk classification group to the low-risk group, suggesting a stabilizing effect on the disease.</p><p>The initial observation from the current analysis, that tiotropium had a greater efficacy than salmeterol in prolonging the time to first COPD exacerbation, confirms the primary results among the total patient population for the POET-COPD trial. Additionally, although not formally tested, our results suggest that the impact of tiotropium versus salmeterol on exacerbations was greater among those patients classified as being at high risk for exacerbations, regardless of whether the ECLIPSE [<xref ref-type="bibr" rid="CR8">8</xref>] or recent GOLD [<xref ref-type="bibr" rid="CR6">6</xref>] definitions are applied. In those patients classified as being at low risk for exacerbations, the results were borderline significant in favor of tiotropium, whereas in the high-risk group, this difference was statistically significant in favor of tiotropium. This might be explained by a lower number of exacerbations in the low-risk group.</p><p>It is noteworthy that the comparable effect observed from treatment with tiotropium versus salmeterol on COPD exacerbations does not appear to be influenced by the concomitant use of background ICS, although the risk ratio is more favorable for tiotropium when compared with salmeterol in both low- and high-risk exacerbator groups that were not using ICS.</p><p>Not only did our results show that treatment with tiotropium or salmeterol resulted in a higher proportion of patients shifting from the high-risk (frequent) to the low-risk (infrequent) exacerbator group, but also that treatment prevented patients at low risk of exacerbations from transitioning into the high-risk group. Many studies have shown that intervention with pharmacotherapy confers benefit to patients with COPD by reducing exacerbations or prolonging the time to first exacerbation [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]; however, few have successfully demonstrated that pharmacotherapy can positively influence the future risk of patients experiencing exacerbations [<xref ref-type="bibr" rid="CR15">15</xref>]. As observed in other interventional trials both in COPD and asthma [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], the overall shift in the exacerbation frequency prior to enrollment versus randomized treatment is remarkable and somehow surprising, particularly in comparison to the relative stability of the phenotype in an observational setting [<xref ref-type="bibr" rid="CR17">17</xref>]. While insufficient background COPD treatment prior to inclusion may at least partially explain this strong shift, other factors may also be relevant such as the definition and documentation of exacerbations [<xref ref-type="bibr" rid="CR18">18</xref>] (e.g., post hoc for history of exacerbations vs. prospectively on trials) as well as recall or reporting of exacerbations [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>We speculate that by intervening early in the disease process, it may therefore be possible to minimize deleterious effects associated with increased frequency and severity of exacerbations in patients with COPD.</p><p>A limitation of the current study is that the POET-COPD trial was not designed to evaluate the effect of tiotropium specifically in different exacerbator phenotypes, nor was it designed to evaluate the effect of tiotropium on mitigating future risk for exacerbations. However, the detailed information regarding exacerbation history before enrollment and subsequently recorded over the course of the study, the large number of patients that participated, and the careful attention to study outcomes provides confidence in the results.</p></sec><sec id="Sec10" sec-type="conclusions"><title>Conclusion</title><p>The results from the current study provide further evidence for intervention with tiotropium as maintenance therapy in COPD patients both at low or high risk for exacerbations.
</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec11"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12325_2015_216_MOESM1_ESM.pptx"><caption><p>Supplementary material 1 (PPTX 218&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><ack><p>Sponsorship, article processing charges, and the open access charge for this study were funded by Boehringer Ingelheim and Pfizer. The POET-COPD trial was funded by Boehringer Ingelheim and Pfizer.</p><p>The authors acknowledge medical writing and editorial assistance from Godfrey Lisk, PhD, Senior Scientific Specialist at PAREXEL, in the form of generation of figures and tables and preparation and revision of the draft manuscript, which was funded by Boehringer Ingelheim and Pfizer. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.</p><p>All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.</p><sec id="d30e1482"><title>Conflict of interest</title><p>Claus F. Vogelmeier gave presentations at symposia and/or served on scientific advisory boards sponsored by Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Janssen, Mundipharma, Novartis, and Takeda. He was responsible for planning and interpretation of data, as well as drafting the manuscript.</p><p>The institution where Kai M. Beeh is employed has received compensation for organizing or participating in advisory boards for Almirall Hermal, AstraZeneca, Boehringer Ingelheim, Chiesi, Cytos, Mundipharma, Novartis, and Revotar Biopharmaceuticals and for participation in scientific meetings or courses supported by various pharmaceutical companies (Almirall Hermal, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, and Takeda) in the past 3&#x000a0;years. His institution has also received consulting fees from Ablynx, Apellis Pharmaceuticals, Chiesi, and Cytos and compensation for the design, performance, or participation in single- or multicenter clinical trials in the past 3&#x000a0;years from several companies, including Almirall, Boehringer Ingelheim, Cytos, GlaxoSmithKline, Mundipharma, Novartis, Pfizer, Revotar Biopharmaceuticals, Sterna AG, and TEVA. He was responsible for planning and interpretation of data, as well as drafting the manuscript. Guus M. Asijee is an employee of Boehringer Ingelheim and was responsible for planning and interpretation of data, as well as drafting the manuscript. Katrin Kupas is an independent statistician hired by Boehringer Ingelheim and was responsible for statistical analysis, interpretation of data, and drafting the manuscript.</p></sec><sec id="d30e1489"><title>Guarantor author</title><p>Guus M. Asijee, PhD.</p></sec><sec id="d30e1494"><title>Contributors</title><p>We thank the patients who participated in the trial; Dr. Klaus Fichtner, Vera Drews, and Nicole Bader for administrative trial support; Dr. Steven Kesten, Dr. Fee R&#x000fc;hmkorf, Dr. Harald Koegler, Dr. Susanne Stowasser, Dr. Brigitta Monz, and Dagmar Selim for scientific advice; Dr. Inge Leimer and Achim M&#x000fc;ller for statistical advice; Michael Betke-Hornfeck for technical trial support; and Christine Meissner and Christina Raabe for data management support.</p></sec><sec id="d30e1499"><title>Compliance with ethics guidelines</title><p>This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.</p></sec><sec id="d30e1504"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Exacerbation rate, health status and mortality in COPD&#x02014;a review of potential interventions</article-title><source>Int J Chron Obstruct Pulmon Dis.</source><year>2009</year><volume>4</volume><fpage>203</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.2147/COPD.S3385</pub-id><pub-id pub-id-type="pmid">19554195</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soler-Cataluna</surname><given-names>JJ</given-names></name><name><surname>Martinez-Garcia</surname><given-names>MA</given-names></name><name><surname>Roman</surname><given-names>SP</given-names></name><name><surname>Salcedo</surname><given-names>E</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Ochando</surname><given-names>R</given-names></name></person-group><article-title>Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2005</year><volume>60</volume><issue>11</issue><fpage>925</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1136/thx.2005.040527</pub-id><pub-id pub-id-type="pmid">16055622</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewoehner</surname><given-names>DE</given-names></name></person-group><article-title>The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease</article-title><source>Am J Med</source><year>2006</year><volume>119</volume><issue>10 Suppl 1</issue><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2006.08.006</pub-id><pub-id pub-id-type="pmid">16996898</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzueto</surname><given-names>A</given-names></name></person-group><article-title>Impact of exacerbations on COPD</article-title><source>Eur Respir Rev</source><year>2010</year><volume>19</volume><issue>116</issue><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1183/09059180.00002610</pub-id><pub-id pub-id-type="pmid">20956179</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>S</given-names></name><etal/></person-group><article-title>A 4-year trial of tiotropium in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>15</issue><fpage>1543</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805800</pub-id><pub-id pub-id-type="pmid">18836213</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name><name><surname>Agusti</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>187</volume><issue>4</issue><fpage>347</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1164/rccm.201204-0596PP</pub-id><pub-id pub-id-type="pmid">22878278</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogendoorn</surname><given-names>M</given-names></name><name><surname>Feenstra</surname><given-names>TL</given-names></name><name><surname>Hoogenveen</surname><given-names>RT</given-names></name><name><surname>Al</surname><given-names>M</given-names></name><name><surname>Molken</surname><given-names>MR</given-names></name></person-group><article-title>Association between lung function and exacerbation frequency in patients with COPD</article-title><source>Int J Chron Obstruct Pulmon Dis.</source><year>2010</year><volume>5</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.2147/COPD.S13826</pub-id><pub-id pub-id-type="pmid">21191438</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Susceptibility to exacerbation in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>12</issue><fpage>1128</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0909883</pub-id><pub-id pub-id-type="pmid">20843247</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelmeier</surname><given-names>C</given-names></name><name><surname>Hederer</surname><given-names>B</given-names></name><name><surname>Glaab</surname><given-names>T</given-names></name><etal/></person-group><article-title>Tiotropium versus salmeterol for the prevention of exacerbations of COPD</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>12</issue><fpage>1093</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1008378</pub-id><pub-id pub-id-type="pmid">21428765</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Glaab</surname><given-names>T</given-names></name><name><surname>Stowasser</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial</article-title><source>Respir Res</source><year>2013</year><volume>14</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-14-116</pub-id><pub-id pub-id-type="pmid">24168767</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><etal/></person-group><article-title>Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>8</issue><fpage>775</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa063070</pub-id><pub-id pub-id-type="pmid">17314337</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dransfield</surname><given-names>MT</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials</article-title><source>Lancet Respir Med.</source><year>2013</year><volume>1</volume><issue>3</issue><fpage>210</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(13)70040-7</pub-id><pub-id pub-id-type="pmid">24429127</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Decramer</surname><given-names>M</given-names></name><name><surname>Ficker</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</article-title><source>Lancet Respir Med.</source><year>2013</year><volume>1</volume><issue>3</issue><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(13)70052-3</pub-id><pub-id pub-id-type="pmid">24429126</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>P</given-names></name></person-group><article-title>Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD</article-title><source>Evid Based Med.</source><year>2014</year><volume>19</volume><issue>3</issue><fpage>116</fpage><pub-id pub-id-type="doi">10.1136/eb-2013-101695</pub-id><pub-id pub-id-type="pmid">24530996</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Efficacy of roflumilast in the COPD frequent exacerbator phenotype</article-title><source>Chest</source><year>2013</year><volume>143</volume><issue>5</issue><fpage>1302</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1378/chest.12-1489</pub-id><pub-id pub-id-type="pmid">23117188</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>B</given-names></name><name><surname>Bridges</surname><given-names>T</given-names></name><name><surname>Kulus</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>AF</given-names></name><name><surname>Berhane</surname><given-names>I</given-names></name><name><surname>Vidaurre</surname><given-names>CF</given-names></name></person-group><article-title>Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma</article-title><source>J Allergy Clin Immunol.</source><year>2009</year><volume>124</volume><issue>6</issue><fpage>1210</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.021</pub-id><pub-id pub-id-type="pmid">19910033</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Mullerova</surname><given-names>H</given-names></name><name><surname>Locantore</surname><given-names>N</given-names></name><etal/></person-group><article-title>Factors associated with change in exacerbation frequency in COPD</article-title><source>Respir Res</source><year>2013</year><volume>14</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-14-79</pub-id><pub-id pub-id-type="pmid">23899210</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>AJ</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Patel</surname><given-names>AR</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Kowlessar</surname><given-names>B</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT)</article-title><source>Eur Respir J</source><year>2014</year><volume>43</volume><issue>3</issue><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1183/09031936.00110913</pub-id><pub-id pub-id-type="pmid">23988767</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langsetmo</surname><given-names>L</given-names></name><name><surname>Platt</surname><given-names>RW</given-names></name><name><surname>Ernst</surname><given-names>P</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name></person-group><article-title>Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>177</volume><issue>4</issue><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1164/rccm.200708-1290OC</pub-id><pub-id pub-id-type="pmid">18048806</pub-id></element-citation></ref></ref-list></back></article>